Exploring Ivermectin, Mebendazole and Fenbendazole as Aggressive Cancer Treatments: Research, Protocols, and Controversies (2025)

By Editorial Team

Introduction

Cancer remains a leading cause of morbidity and mortality worldwide, with an increasing incidence of aggressive and treatment-resistant tumors such as triple-negative breast cancer (TNBC), pancreatic adenocarcinoma, and glioblastoma. Despite significant advances in targeted therapies and immunotherapies, many patients continue to face limited effective options, highlighting an urgent need for novel, affordable, and accessible treatment strategies. 

The high cost of oncology drugs-exceeding $150 billion globally in 2022-and the slow pace of new drug approvals further complicate timely patient access to effective therapies. In this context, drug repurposing-the strategy of identifying new therapeutic uses for existing drugs-has emerged as a promising approach to accelerate cancer treatment development while reducing costs and safety risks.

Among repurposed candidates, antiparasitic drugs such as fenbendazole, mebendazole, and ivermectin have attracted considerable attention due to their demonstrated anticancer activities across multiple preclinical models and emerging clinical case reports. These agents, originally developed to treat parasitic infections, exert multiple mechanisms of actions on cancer cells, including disruption of microtubule dynamics, interference with metabolic pathways, and modulation of oncogenic signaling.

Fenbendazole, a benzimidazole derivative widely used in veterinary medicine, has shown potent anticancer effects by destabilizing microtubules, inducing G2/M cell cycle arrest, and impairing glucose metabolism through inhibition of glucose transporters (GLUT1/4) and hexokinase activity. These actions lead to reduced glycolysis and lactate production, effectively starving cancer cells and overcoming drug resistance, particularly in 5-fluorouracil-resistant colorectal cancer models (Bai et al., 2009; Oral Fenbendazole for Cancer Therapy, 2024; Anti-cancer effects of fenbendazole on 5-fluorouracil-resistant cells, 2022). However, fenbendazole’s poor water solubility and limited oral bioavailability present challenges for achieving therapeutic systemic levels, necessitating formulation improvements and pharmacokinetic optimization.

Mebendazole, a structurally related benzimidazole with better bioavailability and a longer history of human use, similarly disrupts microtubule polymerization and induces apoptosis. It has demonstrated anticancer activity in diverse malignancies, including ovarian cancer, chronic myeloid leukemia, and glioblastoma, with evidence of synergistic effects when combined with tyrosine kinase inhibitors and other chemotherapeutics (Potential and mechanism of mebendazole, 2020; Anticancer potential of mebendazole against chronic myeloid leukemia, 2022; Repurposing Drugs in Oncology, 2014). Mebendazole’s ability to cross the blood-brain barrier further supports its investigation in brain tumors.

Ivermectin, a macrocyclic lactone antiparasitic, exhibits broad-spectrum anticancer effects through mechanisms distinct from benzimidazoles. It inhibits key oncogenic pathways such as STAT3, Wnt/β-catenin, and AKT/mTOR, induces oxidative stress, promotes apoptosis and autophagy, and targets cancer stem cells. Preclinical studies have demonstrated its efficacy across more than 20 cancer types, including breast, colon, lung, and hematologic malignancies, with promising activity against drug-resistant and metastatic tumors (OneDayMD, 2025; Ivermectin, a potential anticancer drug, 2021). Its favorable safety profile at standard doses supports combination regimens with fenbendazole and mebendazole, which may enhance therapeutic outcomes through complementary mechanisms.

Despite encouraging preclinical and anecdotal clinical evidence, these antiparasitic agents remain largely experimental in oncology, with limited randomized controlled trials and regulatory approval for cancer indications. Variability in dosing protocols, access issues, and concerns about off-label use underscore the need for rigorous clinical evaluation. Nonetheless, their low cost, oral administration, and multi-targeted anticancer properties position fenbendazole, mebendazole, and ivermectin as attractive candidates for adjunctive cancer therapy, especially in resource-limited settings.

This review aims to synthesize current knowledge on the anticancer mechanisms, clinical case reports, pharmacokinetics, and safety profiles of fenbendazole, mebendazole, and ivermectin. We discuss their potential roles in overcoming drug resistance, improving patient outcomes, and informing future clinical trials that could integrate these repurposed agents into standard oncology practice.

This guide compiles key resources—including research articles, protocols, and expert insights—exploring their possible roles in cancer therapy.

Ivermectin: Key Resources

Informative Article and Videos

June 10, 2024 - "15 minutes with Dr.Makis" - Episode 018: High Dose IVERMECTIN and CANCER


2024 Studies

  • Baghli et al - Targeting the Mitochondrial-Stem Cell Connection in Cancer Treatment: A Hybrid Orthomolecular Protocol. First-in-the-World Ivermectin, Mebendazole and Fenbendazole Protocol in Cancer has been peer-reviewed and published on Sep.19, 2024. Co-authors include Dr Paul Marik and Dr William Makis.
  • Hayashi et al - Ivermectin Enhances Paclitaxel Efficacy by Overcoming Resistance Through Modulation of ABCB1 in Non-small Cell Lung Cancer.
  • Liu et al - Ivermectin inhibits the growth of ESCC (Esophageal squamous cell carcinoma) by activating the ATF4-mediated endoplasmic reticulum stress-autophagy pathway.
  • Aloss et al - Ivermectin Synergizes with Modulated Electro-hyperthermia and Improves Its Anticancer Effects in a Triple-Negative Breast Cancer Mouse Model.
  • Huang et al - Overcoming flumatinib resistance in chronic myeloid leukaemia: Insights into cellular mechanisms and ivermectin's therapeutic potential.
  • Fan et al - Ivermectin Inhibits Bladder Cancer Cell Growth and Induces Oxidative Stress and DNA Damage
  • Man-Yuan Li et al - Ivermectin induces non-protective autophagy by downregulating PAK1 and apoptosis in lung adenocarcinoma cells
  • Kaur et al - Ivermectin: A Multifaceted drug with a potential beyond anti-parasitic therapy
  • Xing Hu et al - Ivermectin as a potential therapeutic strategy for glioma
  • Yang Song et al - Gene signatures to therapeutics: Assessing the potential of ivermectin against t(4;14) multiple myeloma
  • Goldfarb et al - Lipid-Restricted Culture Media Reveal Unexpected Cancer Cell Sensitivities
  • Newell et al - Therapeutic targeting of nuclear export and import receptors in cancer and their potential in combination chemotherapy
  • One Day MD - IVERMECTIN and CANCER, it has at least 15 anti-cancer mechanisms of action. Can Ivermectin Treat COVID-19 mRNA Vaccine Induced Turbo Cancers? - 9 Ivermectin papers reviewed.

Ivermectin in combination with immunotherapy (Nature Medicine 2021)

Types of Cancer Studied with Ivermectin

Top 5 Turbo Cancers are: Lymphoma, Glioblastoma, Breast, Colon, Lung Cancer.

IVERMECTIN could help with aggressive or "Turbo Cancer", or regular cancers.

Here are studies on IVERMECTIN use in certain types of cancer:
  • BLADDER CANCER - (2024 Fan et al) - Ivermectin Inhibits Bladder Cancer Cell Growth and Induces Oxidative Stress and DNA Damage
  • LUNG CANCER - (2024 Man-Yuan Li et al) - Ivermectin induces nonprotective autophagy by downregulating PAK1 and apoptosis in lung adenocarcinoma cells
  • GLIOMA - (2024 Xing Hu et al) - Ivermectin as a potential therapeutic strategy for glioma
  • MULTIPLE MYELOMA - (2024 Yang Song et al) - Gene signatures to therapeutics: Assessing the potential of ivermectin against t(4;14) multiple myeloma
  • OVARIAN CANCER - (2023 Jawad et al) - Ivermectin augments the anti-cancer activity of pitavastatin in ovarian cancer cells
  • PROSTATE CANCER - (2022 Lu et al) - Integrated analysis reveals FOXA1 and Ku70/Ku80 as targets of ivermectin in prostate cancer
  • COLON CANCER - (2022, Alghamdi et al) - Efficacy of ivermectin against colon cancer induced by dimethylhydrazine in male wistar rats
  • PANCREATIC CANCER - (2022 Lee et al) - Ivermectin and gemcitabine combination treatment induces apoptosis of pancreatic cancer cells via mitochondrial dysfunction
  • MELANOMA - (2022 Zhang et al) - Drug repurposing of ivermectin abrogates neutrophil extracellular traps and prevents melanoma metastasis
  • CERVICAL CANCER - (2022, Qabbus et al) - Ivermectin-induced cell death of cervical cancer cells in vitro a consequence of precipitate formation in culture media
  • HEPATOCELLULAR CARCINOMA - (2022 Lu et al) - Ivermectin synergizes sorafenib in hepatocellular carcinoma via targeting multiple oncogenic pathways
  • OSTEOSARCOMA - (2022 Hu et al) - Repurposing Ivermectin to augment chemotherapy’s efficacy in osteosarcoma
  • GASTRIC CANCER - (2021 Rabben et al) - Computational drug repositioning and experimental validation of ivermectin in treatment of gastric cancer
  • LEUKEMIA - (2020, de Castro et al) - Continuous high-dose ivermectin appears to be safe in patients with acute myelogenous leukemia and could inform clinical repurposing for COVID-19 infection
  • ESOPHAGEAL SCC - (2020, Chen et al) - Ivermectin suppresses tumour growth and metastasis through degradation of PAK1 in oesophageal squamous cell carcinoma
  • CHOLANGIOCARCINOMA - (2019 Intyuod et al) - Anti-parasitic drug ivermectin exhibits potent anticancer activity against gemcitabine-resistant cholangiocarcinoma in vitro
  • BREAST CANCER STEM CELLS - (2018 Dominguez-Gomez et al) - Ivermectin as an inhibitor of cancer stem-like cells.
  • CML (CHRONIC MYELOID LEUKEMIA) - (2018 Wang et al) - Antibiotic ivermectin selectively induces apoptosis in chronic myeloid leukemia through inducing mitochondrial dysfunction and oxidative stress.
  • RENAL CELL CARCINOMA - (2017 Zhu et al) - Antibiotic ivermectin preferentially targets renal cancer through inducing mitochondrial dysfunction and oxidative damage
  • GLIOBLASTOMA - (2016 Liu et al) - Anthelmintic drug ivermectin inhibits angiogenesis, growth and survival of glioblastoma through inducing mitochondrial dysfunction and oxidative stress.

Ivermectin Access and Controversies

Expert Opinion: Dr. William Makis

Dr. Makis emphasizes that Ivermectin has shown anti-cancer activity against over 20 types of cancer. However, due to its low cost and off-patent status, clinical trials remain unlikely. Studies in mice have demonstrated effectiveness in breast, colon, glioblastoma, glioma, and leukemia, but more research is needed for lymphoma, testicular cancer, and sarcomas.

IVERMECTIN acts on Cancer mainly by inhibiting signaling pathways involved in cancer proliferation (Akt, Wnt, mTOR) and also by inhibiting CANCER STEM CELLS.

Access to Ivermectin

In many countries, Ivermectin is available over the counter. However, regulatory bodies often impose restrictions, as seen in cases where physicians were penalized for prescribing it. Advocates argue that such restrictions deny patients access to potentially life-saving treatments.


Fenbendazole: Key Resources

Fenbendazole, another antiparasitic, exhibits at least 12 anti-cancer mechanisms. Studies indicate its effectiveness against triple-negative breast cancer, colon cancer, glioma, and leukemia. The ketogenic diet may enhance its therapeutic effects.


Oct.3, 2023 - FENBENDAZOLE and CANCER - at least 12 Anti-Cancer mechanisms of action. Not approved by FDA. Cheap. Safe. Kills aggressive cancers. Why no Clinical Trials? Nine research papers reviewed.

2024 Fenbendazole Studies

  • Nguyen et al - Oral Fenbendazole for Cancer Therapy in Humans and Animals.
  • Liang et al - Synergistic intravesical instillation for bladder cancer: CRISPR-Cas13a and fenbendazole combination therapy.
  • Rodrigues et al - Repurposing mebendazole against triple-negative breast cancer CNS metastasis.
  • Eid et al - Investigating the Promising Anticancer Activity of Cetuximab. and Fenbendazole Combination as Dual CBS and VEGFR-2 Inhibitors and Endowed with Apoptotic Potential
  • Park et al) - The microtubule cytoskeleton: A validated target for the development of 2-Aryl-1H-benzo[d]imidazole derivatives as potential anticancer agents
  • Matsuo et al - Parbendazole as a promising drug for inducing differentiation of acute myeloid leukemia cells with various subtypes

2023 Fenbendazole Studies

  • Semkova et al - Redox-mediated Anticancer Activity of Anti-parasitic Drug Fenbendazole in Triple-negative Breast Cancer Cells.
  • 2023, Dec, Iragavarapu-Charyulu et al - A novel treatment to enhance survival for end stage triple negative breast cancer using repurposed veterinary anthelmintics combined with gut‑supporting/immune enhancing molecules.
  • 2023 Nov, Aliabadi et al - In vitro and in vivo anticancer activity of mebendazole in colon cancer: a promising drug repositioning.
  • 2023 Nov, Jung et al - Fenbendazole Exhibits Differential Anticancer Effects In Vitro and In Vivo in Models of Mouse Lymphoma.
  • 2023 Sep, Garg et al - Network pharmacology and molecular docking study-based approach to explore mechanism of benzimidazole-based anthelmintics for the treatment of lung cancer
  • 2023 Jun, Mukherjee et al - Ketogenic diet as a metabolic vehicle for enhancing the therapeutic efficacy of mebendazole and devimistat in preclinical pediatric glioma
  • 2023 Feb, Lee et al - Benzimidazole and its derivatives as cancer therapeutics: The potential role from traditional to precision medicine

Experimental Cancer Protocols

For aggressive cancers, high-dose Fenbendazole (444-888mg/day) or Mebendazole (up to 4g/day) may be considered. Clinical trials support Mebendazole’s safety at high doses.
  • You can look at fenbendazole.org for suggested dosing and dose calculator
  • Dr.Tom Rogers, Founder of “Performance Medicine” has similar protocols.
  • For anyone COVID-19 mRNA Vaccinated diagnosed with cancer (Turbo Cancer), I’d probably be looking at starting at 444 mg a day.
  • For particularly aggressive Turbo Cancers or bad cases, I’d even consider pushing towards 888 mg/day (444 mg twice a day) or 1000 mg/day.
  • Highest dosing I’ve seen is 30-50mg/kg/day for 5 days, based on the “Merck Manual”, however very few claim to have taken this dose.
  • Fenbendazole can elevate liver function tests, so it would be a good idea to have a family doctor monitor those
Related: Fenbendazole cancer success stories (More than 100 case reposts)

Mebendazole: Key Resources

So far, several studies in the literature have used 200mg/day with some success, however given that it is safe to go up to 4g/day, when we’re dealing with aggressive mRNA Induced Turbo Cancers, 200mg/day is probably not sufficient.

    Here are the references for this dosing schedule:

  • For Maximum dose of 4g/day being safe, that’s from a Phase 2 Clinical Trial for Gastrointestinal Cancer: (2021 Mansoori et al)

  • (2021 Chai et al) - summarizes the various studies that have looked at Mebendazole in Cancer and the doses used.

  • Why Mebendazole over Albendazole (2021 Chai et al):

    “However, because of the toxicity of albendazole, for example, neutropenia due to myelosuppression, if high doses are used for a prolonged time, mebendazole is currently more popularly used than albendazole in anti-cancer clinical trials.”
  • Precaution: Importantly, a combined use of mebendazole (>500 mg) and metronidazole (>500 mg) is prohibited because severe and rare fatal adverse events such as Stevens-Johnson syndrome (or toxic epidermal necrosis) may occur. The risk increased with increasing doses of metronidazole but not mebendazole, and there may be a synergistic interaction between mebendazole and metronidazole. (2003 Chen et al)

2024 Mebendazole Study

  • Aydin et al - Case report: Precision guided reactive cancer management: molecular complete response in heavily pretreated metastatic CRC (Colo-Rectal Cancer) by dual immunotherapy and mebendazole.
    • Nivolumab (anti-PD-1) was given at a monthly dose of 400 mg, 
    • Ipilumab (anti-CTLA-4) was administered every two months at a dose of 50 mg, 
    • Lenvatinib (Lenvima) was prescribed at a daily dosage of 10 mg, and 
    • Mebendazole was used twice daily at a dose of 100 mg each time.

New & Improved Joe Tippens Protocol

The holy grail turbo cancer treatment may just be the synergistic combination therapy of Fenbendazole AND Ivermectin as follows:

  • Fenbendazole (300mg, 6 days a week) or in the case of severe turbo cancers up to 1 gram/day.

  • Ivermectin* (24mg, 7 days a week) or in the case of severe turbo cancers up to 1mg/kg/day (Find a Doctor)

  • Bio-Available Curcumin (600mg per day, 7 days a week).

  • Vitamin D (62.5 mcg [2500 IU] seven days a week).

  • Lifestyle: Eliminate sugar (BMJ 2023), adopt a whole-food diet, avoid ultra-processed foods (BMJ 2024), prioritize sleep, and manage stress.

Please note that this protocol now includes the vital Vitamin D addition, with the one day off for the fenbendazole administration. This protocol represents the most comprehensive and cutting edge repurposed drug and vitamin treatment approach to date.

*Note: If you are already taking ivermectin and mebendazole, you may not need to add fenbendazole. Always consult your doctor before making any changes to your treatment plan.
Source: Adapted from OneDayMD.com. https://www.onedaymd.com/2024/11/fenbendazole-and-cancer-15-minutes-with.html (November 2024).

Fenbendazole and Mebendazole Cost

Fenbendazole is cheap. If big pharma is going to make money (especially in cancer treatment), they need an expensive compound and Fenbendazole isn’t it.

Dr. William Makis’s Take on Fenbendazole & Mebendazole

While research on Fenbendazole and cancer continues, scientists are increasingly focusing on other compounds in the Benzimidazole family, including Mebendazole, Albendazole, and Parbendazole. 

If I were diagnosed with mRNA-induced turbo cancer as a male in my 40s, I would strongly consider a combination of Ivermectin (1mg/kg/day) and Fenbendazole (444mg/day). This decision would be based on numerous peer-reviewed studies, ongoing clinical trials, and existing research.

"Everyone’s situation is different, but it is crucial to arm yourself with medical knowledge that oncologists may not provide, either due to a lack of awareness or fear of professional risk."

Scam and Fraud Alert!

Scam Alert (January 2025): Dr. Makis warns of scams on Facebook, WhatsApp, and Telegram using his identity. Contact him only at makisw79@yahoo.com.

Dr William Makis posted this alert on X/Twitter (Jan 2025):

There are many SCAMS now using my photos on Facebook, WhatsApp and Telegram. I am NOT on any of these platforms! I also don't have a website. 

You can only reach me via: makisw79@yahoo.com. 
Any other variation of this email is a fraud.

Research Gaps and Future Directions

We recognize that double-blind, prospective, randomized controlled trials (RCTs) remain the gold standard in medical research. However, alternative study designs, such as N=1 trials, open-label studies, and real-world data analysis, provide practical insights—especially for rare or advanced cancers where large-scale RCTs may be impractical due to cost and time constraints. While these methods lack the rigorous controls of RCTs and are more susceptible to bias and confounding factors, they still offer valuable evidence that should not be overlooked.

For patients with Stage 4 or aggressive cancers, considering all available treatment options is essential, given the high-risk, high-reward nature of their condition. In such life-threatening scenarios, patients should have the "right to try" experimental or off-label treatments if standard options have been exhausted.

While clinical guidelines are informed by research, real-world patient care is not always dictated by clinical trials alone. Personalized treatment can be seen as a series of N=1 trials, where multiple interventions are carefully tested on an individual basis. By combining empirical evidence, clinical expertise, and real-time assessments—including cancer markers and PET scans—physicians can closely monitor treatment responses and adapt strategies quickly to maximize both effectiveness and safety.

Conclusion

Ivermectin, Fenbendazole, and Mebendazole show promise as experimental cancer treatments, supported by emerging research across multiple cancer types. However, clinical trial data remain limited. Patients should consult healthcare professionals before pursuing these protocols.



RELATED: 







Read More: This article is part of the Winning the War on Cancer series.



Ivermectin and mebendazole, both approved for human use, are now available in the U.S.

Researched and approved by Dr. Peter McCullough.
  • Prescribed by licensed medical professionals
  • Compounded and dispensed by a licensed US-based pharmacy
  • Approved for human use
Where to buy Ivermectin and Mebendazole Formula: Available on The Wellness Company's website. Here is the link: Ivermectin and Mebendazole.

Comments

Post a Comment

Popular posts from this blog

Fenbendazole vs Ivermectin for Cancer: Differences and Which Is Better?

By Editorial Team
Image
Cancer patients are increasingly inquiring about the use of the anthelmintic drugs Fenbendazole (FenBen) and Ivermectin (IVM) as potential treatments for cancer. Notably, these patients typically fall into two distinct groups, neither of which represents the usual stage 1 or 2 cancer cases where conventional therapies often show promise. The first group consists of older men whose lung or prostate cancer has recurred. Having undergone conventional treatments previously without success, they express skepticism about its effectiveness this time around. The second, larger group comprises younger patients under 40 dealing with aggressive breast cancer, colorectal cancer, or lymphoma—forms of early-onset cancers that appear to lack the typical mutations observed in traditional cases. This article aims to delve into the differences between Fenbendazole and Ivermectin by examining their mechanisms of action, approved uses, and the latest research on their efficacy across various medical con...
Read more

Top 10 Cancer Fighting Supplements: Evidence Based Literature Review (2025)

By Editorial Team
Image
Are you overwhelmed by conflicting advice on cancer, diet, and supplements ? You’re not alone. With so many claims out there, it’s hard to separate fact from fiction . Can certain foods lower your cancer risk ? Are some foods increasing it without you realizing? What about vitamin and mineral supplements —do they help prevent cancer, or could they actually increase your risk ? The term " anti-cancer supplements " can be misleading. While some nutrients support the body in cancer prevention or treatment, others may interfere with therapies or even pose risks. This guide compiles over 300 scientific references on cancer, diet, and supplements—helping you navigate the facts with confidence. Understanding Supplements and Cancer: What You Should Know Dietary supplements are not regulated like medications. Unlike prescription drugs, supplements aren’t rigorously tested by the FDA for safety or effectiveness before hitting the market. Not all supplements are beneficia...
Read more

Fenbendazole Dosage for Cancer in Humans: Benefits, Risks, and Guidelines (2025)

By Editorial Team
Image
What is Fenbendazole? Fenbendazole is an anthelmintic drug commonly used to treat parasitic infections in animals. However, recent research and anecdotal reports suggest it may have potential anticancer properties in humans. How Does Fenbendazole Work for Cancer? Fenbendazole is believed to work by disrupting microtubules in cancer cells, leading to cell cycle arrest and apoptosis (cell death). Some studies suggest it may also modulate glucose metabolism, limiting cancer cell energy supply. Recommended Fenbendazole Dosage for Cancer in Humans The commonly referenced Joe Tippens Protocol suggests the following dosage: Potential Side Effects of Fenbendazole in Humans While generally considered safe, potential side effects may include: Gastrointestinal discomfort (nausea, diarrhea, bloating) Liver enzyme elevation (rare) Bone marrow suppression (rare) Safety and Precautions Medical Supervision: Always consult with a doctor, especially if combining with other treatments. Drug Interaction...
Read more

Fenbendazole and Ivermectin for Cancer Case Series: Over 150 Case Reports (2025)

By Editorial Team
Image
  Contents: Editor's Preface Introduction Fenbendazole and Ivermectin Case Series Compilation (alphabetical) Breast Cancer Success Stories  (21 cases) Brain Cancer success stories  (including Glioblastoma and Astrocytoma) Bile Duct Cancer  (Cholangiocarcinoma) Bladder Cancer Success Stories  (7 cases) Cervical Cancer  (3 cases) Colorectal Cancer  (20 cases) Esophageal and Stomach cancer Endometrial Cancer (4 cases) Gastric (Stomach) cancer (3 cases) Head and Neck Cancer (7 cases) Kidney Cancer Case Series (8 cases) Liver Cancer (2 cases) Lung Cancer (11 cases) Leukemia (2 cases) Lymphoma (4 cases) Melanoma (Skin Cancer) Multiple Myeloma Myelodysplastic Syndrome Oral Cancer Ovarian Cancer (2 cases) Pancreatic Cancer (15 cases) Prostate Cancer (20 cases) Sarcoma (2 cases) Skin Cancer (8 cases) Thymus cancer Turbo Cancer Uterine cancer Conclusion Editor's Preface We began this article with just a handful of cases, but it has since expanded to include over...
Read more

Cancer Prevention 101: I-Prevent Cancer Protocol (2025 Edition)

By Editorial Team
Image
Cancer prevention is a multifaceted endeavor, encompassing diet, lifestyle, and supplementation. The I-PREVENT CANCER protocol offers evidence-based strategies to mitigate cancer risk. Source: AACR Cancer Progress Report 2024 Understanding Cancer and Its Causes Cancer arises from genetic mutations influenced by lifestyle and environmental factors. Diet, physical inactivity, tobacco use, and exposure to carcinogens significantly contribute to cancer development. ​ Dietary Approaches for Cancer Prevention Adopting a plant-based or Mediterranean diet can reduce cancer risk. These diets emphasize fruits, vegetables, whole grains, and healthy fats while limiting processed foods, sugars, and alcohol. Such nutritional choices provide essential antioxidants and nutrients that support cellular health. ​ Lifestyle Modifications Key lifestyle changes include: ​ Smoking Cessation : Eliminates exposure to numerous carcinogens. ​ Weight Management : Maintains hormonal balance and reduc...
Read more

Fenbendazole and Metastatic Cancer: the 2021 Stanford University Case Series

By Editorial Team
Image
What is the "Stanford Fenbendazole Protocol"? I bet you've never heard of the "Stanford Fenbendazole Protocol" for treating Cancer. Yet, it exists. But it's heavily suppressed by search engines and mainstream Oncology, especially in the United States and Canada. In 2021 a group at Stanford University Medical Center, Department of Medicine, published a Case Series (Clin. Oncol. Case Rep 2021)* on a "forbidden" repurposed drug, Fenbendazole. *Note: Clinical Oncology Case Reports is a peer-reviewed International clinical and medical oncology and cancer research Journal. Clinical Oncology Case Reports (COCR) is a high-impact multidisciplinary journal focus on the area of clinical and medical investigation. They wrote about 3 cases of Stage 4 Cancer patients who self-treated and cured their cancers.   Case 1: 63 year old man with a Stage 4 Renal Cell Carcinoma (clear cell) , a 5.3cm mass and mets to pancreas and bone, failed 3 lines of chemo. He ...
Read more

Eat These Foods to Starve Cancer Cells to Death (2025)

By Editorial Team
Image
Some people may not realize this, but many people have cancer cells in their bodies without presenting much danger. Fortunately, there are some common foods that can cut off cancer cell’s nutrient supply and starve them to death. Autopsies of individuals who died of trauma often reveal microscopic colonies of cancer cells , also known as in situ tumors. Some people call them “disease-free cancers.” For instance,  researchers  in Denmark performed autopsies on women aged 40 to 50, who  never  had cancer during their lifetime, and found that 39 percent of them had small cancerous lesions in their breasts. Only 1 percent of women in this age group would be diagnosed with breast cancer. Examination  of some men in their 60s showed that 46 percent of them had histological evidence of prostate cancer, which is consistent with the findings of the autopsy study. However, the prevalence of prostate cancer in men aged 60 to 70 is actually around 1 percent....
Read more

Ivermectin to Treat Cancer in Humans (2024)

By Editorial Team
Image
Ivermectin is a widely used antiparasitic drug that's listed on the World Health Organization's essential medicines list 1   and approved by the U.S. Food and Drug Administration. In low- and middle-income countries, ivermectin is commonly used to treat parasitic diseases including onchocerciasis (river blindness), strongyloidiasis and other diseases caused by soil-transmitted helminthiasis, or parasitic worms. 2 The drug is also used to treat scabies and lice. It's estimated that the total number of ivermectin doses distributed is equal to one-third of the world's population and, as such, "ivermectin at the usual doses (0.2–0.4 mg/kg) is considered extremely safe for use in humans." 3 Ivermectin also has demonstrated antiviral and anti-inflammatory properties and made headlines for its potential role in treating COVID-19 4  — although much of the positive press has been censored and falsely labeled misinformation. 5  Now researchers are highlighting another p...
Read more

Integrative Oncology Treatment Directory and Resource Page

By Editorial Team
Image
POPULAR Hyperthermia  Therapy Hyperthermia is defined as raising the temperature of the whole body or a part of the body above normal for a defined period of time. Scientific evidence shows hyperthermia may shrink tumors by damaging cancer cell proteins and structures within the cancer cells themselves. Hyperthermia is almost always used in conjunction with other cancer therapies.  Treatment use: Patients are usually recommended to use saunas 2-3 times per week, depending on the doctor's recommendation. Hyperthermia is a 45-minute treatment. IV Therapies Alpha Lipoic Acid IV Amino Acid IV Antioxidant Artemisinin Curcumin IV Detoxification IV Therapy (Chelation) DMSO High Dose Vitamin C Hydration Iv ...
Read more